Michailidou, Despina
Duvvuri, Bhargavi
Kuley, Runa
Cuthbertson, David
Grayson, Peter C.
Khalidi, Nader A.
Koening, Curry L.
Langford, Carol A.
McAlear, Carol A.
Moreland, Larry W.
Pagnoux, Christian
Seo, Philip
Specks, Ulrich
Sreih, Antoine G.
Warrington, Kenneth J.
Mustelin, Tomas
Monach, Paul A.
Merkel, Peter A.
Lood, Christian
Funding for this research was provided by:
NIH (#5T32HL007028-44, #R21AR075134, #1R21EY029391)
Pfizer US Pharmaceuticals Group grant (53857367)
National Center for Advancing Translational Sciences (#U54 AR057319)
National Center for Research Resources (#U54 RR019497)
Article History
Received: 26 January 2022
Accepted: 16 June 2022
First Online: 29 June 2022
Declarations
:
: The study was approved by the regional ethics board at the University of Washington, Seattle, WA, (#3100).
: Informed written consent was obtained from all participants in accordance with the Helsinki Declaration.
: Dr. Michailidou received Advisory Board fees from ChemoCentryx. Dr. Khalidi received clinical trial support from BMS, Sanofi, and Abbvie; travel support from Astra Zeneca; and an Advisory Board fee from Roche. Dr. Koening served on the advisory board for Chemocentryx and Genentech. Dr. Specks reports receiving funds for the following activities: Consulting: AstraZeneca, ChemoCentryx. Research Support: AstraZeneca, GlaxoSmithKline, Bristol-Myers Squibb, Genentech/Roche, InflaRx. Dr. Sreih works at Bristol-Myers Squibb and owns Astra Zeneca and Alexion Stocks. Dr. Warrington received clinical trial support from Eli Lilly and Kiniksa. Dr. Monach received consulting fees from Kiniksa, Celgene/BMC, and ChemoCentryx. Dr. Merkel reports receiving funds for the following activities: Consulting and Research Support: AbbVie, AstraZeneca, Boeringher-Ingelheim, Bristol-Myers Squibb, ChemoCentryx, Forbius, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, InflaRx, Takeda. Consulting only: CSL Behring, Dynacure, EMDSerono, Janssen, Kiniksa, Kyverna, Magenta, MiroBio, Neutrolis, Novartis, Pfizer, Sparrow, Talaris. Royalties: UpToDate. Dr. Mustelin received consulting fees from Cugene, Kiniksa, Miro Bio, and QiLu Pharmaceuticals; has an ownership share in Amdax; and has received research funding from Gilead Sciences. Dr. Lood received research funding from Exagen Inc, Pfizer, Gilead Sciences, and Eli Lilly.